Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 834,302 shares at $20.06 ($16.5M) on 2026-04-20, disclosed to the SEC on 2026-04-22.
Scheduled sale ($16.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.06 | 1,401 | $28K | 0.2% |
| 2 | $20.06 | 56,368 | $1.1M | 6.9% |
| 3 | $20.06 | 71,676 | $1.4M | 8.7% |
| 4 | $20.06 | 142,604 | $2.9M | 17.4% |
| 5 | $19.51 | 1,398 | $27K | 0.2% |
| 6 | $19.51 | 56,228 |
| $1.1M |
| 6.7% |
| 7 | $19.51 | 71,499 | $1.4M | 8.5% |
| 8 | $19.51 | 142,253 | $2.8M | 16.8% |
| 9 | $20.05 | 1,530 | $31K | 0.2% |
| 10 | $20.05 | 15 | $301 | 0.0% |
| 11 | $20.05 | 605 | $12K | 0.1% |
| 12 | $20.05 | 769 | $15K | 0.1% |
| 13 | $19.68 | 1,485 | $29K | 0.2% |
| 14 | $19.68 | 59,663 | $1.2M | 7.1% |
| 15 | $19.68 | 75,866 | $1.5M | 9.1% |
| 16 | $19.68 | 150,942 | $3.0M | 18.0% |
| Total | $19.75 avg | 834,302 | $16.5M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |